Insight
David Tougeron
David Tougeron/oncologypro.esmo.org

David Tougeron: Nal-IRI/LV5-FU Versus Paclitaxel as Second-line Therapy

David Tougeron, Professor at Poitiers University Hospital, shared a post on LinkedIn:

“Our last published FFCD PRODIGE trial, that I have coordinated, evaluating second line chemotherapy in metastatic oesophagus squamous cell carcinoma. Both paclitaxel and 5FU Naliri have poor efficacy but paclitaxel had a better safety profile.”

Title: Nal-IRI/LV5-FU versus paclitaxel as second-line therapy in patients with metastatic esophageal squamous cell carcinoma (PRODIGE 62-FFCD 1701-OESIRI)

Authors: David Tougeron, Laurent Mineur, Aziz Zaanan, Melissa Kadi, Catherine Poisson Ligeza, Vincent Bourgeois, Jérôme Martin-Babau, Aurélie Fadin, Véronique Jestin le Tallec, Valérie Ly Lebrun, Olivier Dubreuil, Faiza Khemissa Akouz, Elsa Thimonier, Olivier Bouché, Astrid Lièvre, Frédéric Di Fiore, Thierry Lecomte, Côme Lepage, Vincent Hautefeuille

Read the Full Article.

David Tougeron

More posts featuring David Tougeron.

Astrid Lievre Aurélie Fadin Aziz Zaanan cancer Catherine Poisson Ligeza Côme Lepage David Tougeron Elsa Thimonier Faiza Khemissa Akouz Frédéric Di Fiore Jérôme Martin-Babau Laurent Mineur Melissa Kadi Olivier Bouché Olivier Dubreuil OncoDaily Oncology Thierry Lecomte Valérie Ly Lebrun Véronique Jestin le Tallec Vincent Bourgeois Vincent Hautefeuille